Persephone Biosciences (YC W18) — We are using the gut microbiome to end cancer
Persephone Biome develops live biotherapeutic products to modulate the metabolism of gut microbes, for applications in disease prevention and cure. We take a unique engineering approach using systems and synthetic biology to understand the complexities of the microbiome.
Persephone Biosciences is a Y Combinator company in the Winter 2018 batch. Its directory entry describes it as: We are using the gut microbiome to end cancer. The founders listed are Stephanie Culler (Founder/CEO), Stephen Van Dien (Founder/CTO) (Y Combinator directory entry, November 3, 2017).
Get an email when Persephone Biosciences changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Persephone Biosciences?
Get the full cited report on Persephone Biosciences
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
Persephone Biome develops live biotherapeutic products to modulate the metabolism of gut microbes, for applications in disease prevention and cure. We take a unique engineering approach using systems and synthetic biology to understand the complexities of the microbiome.
Stephanie Culler
Founder/CEO
Stephen Van Dien
Founder/CTO
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Persephone Biosciences?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Persephone Biosciences: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Persephone Biosciences covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Persephone Biosciences: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Persephone Biosciences (YC W18) — We are using the gut microbiome to end cancer. MentionFox, 2026-10-27. https://mentionfox.com/funding/yc-persephone-biosciences
